Keeping You Connected

The SFMMS keeps you up to date on the latest news,
policy developments, and events

San Francisco Marin Medical Society Blog

Article References for June/July 2016 San Francisco Medicine

June 23, 2016 San Francisco Medicine Keith Block, Matthew Cooperberg, San Francisco Medicine, Ted Schettler 0

References cited for "Life Over Cancer: Achieving a Survivor’s Edge" by Keith I. Block, MD.

  1. Block, K.I. Life Over Cancer. Bantam Books, New York, NY. 2009.
  2. Elwood, P.C., Morgan, G., Pickering, J.E. et al. “Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.” PLoS One. 2016 Apr 20;11(4):e0152402.
  3. McMillan, D.C. “The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.” Cancer Treat Rev. 2013 Aug;39(5):534-40.
  4. Shrotriya, S., Walsh, D., Bennani-Baiti, N. et al. “C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.” PLoS One. 2015 Dec 30;10(12):e0143080.
  5. Ryan, J.L., Heckler, C.E., Ling, M. et al. “Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients.” Radiat Res. 2013 Jul;180(1):34-43.
  6. Pappalardo, G., Almeida, A., Ravasco, P. “Eicosapentaenoic acid in cancer improves body composition and modulates metabolism.” Nutrition. 2015 Apr;31(4):549-55.
  7. Innominato, P.F., Roche, V.P., Palesh, O.G. et al. “The circadian timing system in clinical oncology.” Ann Med. 2014 Jun; 46:4, 191-207.
  8. Shukla, P., Gupta, D., Bisht, S.S. “Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma.” Cancer 2010 April 15; 116(8):2031-5.

  9. Block, K.I., Gyllenhaal, C., Lowe, L. et al. “Designing a broad-spectrum integrative approach for cancer prevention and treatment.” Semin Cancer Biol. 2015 Dec;35 Suppl:S276-304.

References cited for "Prostate Cancer Screening: Where We Are and Where We Should Go" by Matthew R. Cooperberg, MD, MPH, FACS.

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.
  2. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited. Cancer. May 2012:n/a–n/a. doi:10.1002/cncr.27594.
  3. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–134. doi:10.7326/0003-4819-157-2-201207170-00459.
  4. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. doi:10.1016/S0140-6736(14)60525-0.
  5. Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial. Eur Urol. 2015;68(3):354–360. doi:10.1016/j.eururo.2014.12.006.
  6. Shoag JE, Mittal S, Hu JC. Reevaluating PSA Testing Rates in the PLCO Trial. N Engl J Med. 2016;374(18):1795–1796. doi:10.1056/NEJMc1515131.
  7. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7(4):303–311. doi:10.1177/1740774510374091.
  8. Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62(1):1–15. doi:10.1016/j.eururo.2012.02.029.
  9. Kaffenberger SD, Penson DF. The Politics of Prostate Cancer Screening. Urol Clin North Am. 2014;41(2):249–255. doi:10.1016/j.ucl.2014.01.004.
  10. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011;29(13):1736–1743. doi:10.1200/JCO.2010.31.9004.
  11. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–1123. doi:10.1200/JCO.2009.26.0133.
  12. Tasian GE, Cooperberg MR, Cowan JE, et al. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012;30(2):155–160. doi:10.1016/j.urolonc.2009.12.019.
  13. Barocas DA, Mallin K, Graves AJ, et al. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. J Urol. 2015;194(6):1587–1593. doi:10.1016/j.juro.2015.06.075.
  14. Gulati R, Tsodikov A, Etzioni R, et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014;120(22):3519–3526. doi:10.1002/cncr.28932.
  15. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ. 2013;346(apr15 5):f2023–f2023. doi:10.1136/bmj.f2023.
  16. Vickers AJ, Edwards K, Cooperberg MR, Mushlin AI. A simple schema for informed decision making about prostate cancer screening. Ann Intern Med. 2014;161(6):441–442. doi:10.7326/M14-0151.
  17. Cooperberg MR, Hinotsu S, Namiki M, et al. Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy. J Clin Oncol. 2009;27(26):4306–4313. doi:10.1200/JCO.2008.21.5228.
  18. Leapman MS, Nguyen HG, Cooperberg MR. Clinical Utility of Biomarkers in Localized Prostate Cancer. Curr Oncol Rep. 2016;18(5):30. doi:10.1007/s11912-016-0513-1.
  19. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015;314(1):80–82. doi:10.1001/jama.2015.6036.
  20. Womble PR, Montie JE, Ye Z, et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol. 2015;67(1):44–50. doi:10.1016/j.eururo.2014.08.024.

References cited for "The Ecology of Breast Cancer:  Opportunities for Prevention" by Ted Schettler, MD, MPH.

  1. Schettler, T. “The Ecology of Breast Cancer:  The Promise of Prevention and the Hope for Healing.” October 2013. Available at: http://tinyurl.com/j3y42yv Includes more detail and citations for conclusions in this brief summary.   
  2. Colditz, G., Bohlke, K., Berkey, C. “Breast cancer risk reduction starts early: prevention must also.” Breast Cancer Res Treat. 2014; 145(3):567-579.
  3. Berkey, C.S., Gardner, J.D., Frazier, A.L., Colditz, G.A. “Relation of childhood diet and body size to menarche and adolescent growth in girls.” Am J Epidemiol. 2000;152:446-452.
  4. Liu, Y., Colditz, G., Cotterchio, M. et al. “Adolescent dietary fiber, vegetable fat, vegetable protein, and nut intakes and breast cancer risk,” Breast Cancer Res Treat. 2014;145:461-470.
  5. Messina, M., Hilakivi-Clarke, L. “Early intake appears to be the key to the proposed protective effects of soy intake against breast cancer.” Nutr Cancer. 2009; 61(6):792-798.
  6. Hopkins, D., Steer, C., Northstone, K., Emmett, P. “Effects on childhood body habitus of feeding large volumes of cow or formula milk compared with breastfeeding in the latter part of infancy.” Am J Clin Nutr. 2015; 102(5):1096-1103.
  7. De Beer. “Dairy products and physical stature.” Econ Hum Biol. 2012; 299-309.
  8. Berkey, C., Colditz, G., Rockett, H. et al. “Dairy consumption and female height growth: prospective cohort study.” Cancer Epidemiol Biomarkers Prev. 2009;18:1881-1887.
  9. Victora, C., Bahl, R., Barros, A., Franca, G. et al. “Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect.” Lancet 2016; 387(10017):475-490.
  10. The Institute of Medicine (20 ng/mL) and the Endocrine Society (30 ng/mL) differ with respect to what they believe is the cut point for insufficient levels of 25(OH)D3, the circulating form of the hormone measured in blood. Regardless, levels fall below either level in many people in the general population.
  11. Breast Cancer Fund. “Working Women and Breast Cancer.” Available at: http://www.breastcancerfund.org/media/publications/reports/working-women-and-breast-cancer.html?referrer=https://www.google.com/
  12. Hilakivi-Clarke, L. “Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters.” Breast Cancer Res. 2014; 16(2):208.
  13. Cohn B, Wolff M, Cirillo P, Sholtz R. “DDT and breast cancer in young women: new data on the significance of age at exposure.” Environ Health Perspect. 2007; 115(10):1406-1414.
  14. Cohn, B., La Merrill, M., Krigman, N., Yey, G. et al. “DDT exposure in utero and breast cancer.” J Clin Endocrinol Metab. 2015; 100(8):2865-2872.
  15. http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Exposure-to-Toxic-Environmental-Agents
  16. http://www.cancer.gov/news-events/press-releases/2011/IARCcellphoneMay2011
  17. West, J., Kapoor, N., Liao, S.Y., Chen, J. et al. “Multifocal breast cancer in young women with prolonged contact between their breasts and their cellular phones.” Case Reports in Medicine. 2013; Article ID 354682.  Available at http://www.hindawi.com/journals/crim/2013/354682/


Comments are closed.

Categories

Archives

Not a SFMMS member?

Join 43,000 physicians making a direct impact on health care legislation.

JOIN SFMMS